Bank of America Forecasts Strong Price Appreciation for Chemed (NYSE:CHE) Stock

Chemed (NYSE:CHE) had its price target raised by equities researchers at Bank of America from $450.00 to $510.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Bank of America‘s price target would suggest a potential upside of 4.56% from the company’s current price.

CHE has been the subject of a number of other research reports. Royal Bank Of Canada boosted their price objective on shares of Chemed from $422.00 to $436.00 and gave the company a “sector perform” rating in a report on Monday, April 27th. Wall Street Zen cut Chemed from a “buy” rating to a “hold” rating in a research note on Monday, June 8th. Weiss Ratings raised Chemed from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, April 29th. Finally, Zacks Research raised Chemed from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. One research analyst has rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, Chemed currently has a consensus rating of “Hold” and a consensus price target of $480.25.

Chemed Stock Performance

NYSE:CHE opened at $487.76 on Thursday. The stock has a 50 day simple moving average of $443.16 and a 200 day simple moving average of $428.70. The stock has a market cap of $6.47 billion, a P/E ratio of 26.58, a PEG ratio of 1.81 and a beta of 0.52. Chemed has a 1-year low of $365.20 and a 1-year high of $493.47. The company has a current ratio of 0.85, a quick ratio of 0.83 and a debt-to-equity ratio of 0.11.

Chemed (NYSE:CHE) last posted its earnings results on Thursday, April 23rd. The company reported $5.65 earnings per share for the quarter, topping analysts’ consensus estimates of $5.30 by $0.35. Chemed had a return on equity of 27.18% and a net margin of 10.23%.The company had revenue of $657.51 million during the quarter, compared to the consensus estimate of $659.22 million. During the same quarter last year, the firm earned $5.63 earnings per share. The company’s revenue was up 1.6% on a year-over-year basis. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. Research analysts anticipate that Chemed will post 22.67 earnings per share for the current year.

Insider Buying and Selling at Chemed

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $421.13, for a total value of $842,260.00. Following the sale, the chief executive officer owned 90,219 shares of the company’s stock, valued at approximately $37,993,927.47. This trade represents a 2.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Andrea R. Lindell sold 1,347 shares of Chemed stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $447.33, for a total value of $602,553.51. Following the completion of the transaction, the director owned 4,578 shares in the company, valued at approximately $2,047,876.74. The trade was a 22.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 3.33% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CHE. Northwestern Mutual Wealth Management Co. lifted its stake in Chemed by 2,444,879.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 5,550,103 shares of the company’s stock valued at $2,374,667,000 after purchasing an additional 5,549,876 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Chemed by 4.4% in the 4th quarter. JPMorgan Chase & Co. now owns 521,900 shares of the company’s stock valued at $223,301,000 after acquiring an additional 21,932 shares during the last quarter. AQR Capital Management LLC grew its position in Chemed by 89.2% during the 4th quarter. AQR Capital Management LLC now owns 325,579 shares of the company’s stock worth $139,302,000 after acquiring an additional 153,469 shares during the last quarter. TD Asset Management Inc increased its holdings in Chemed by 7.5% in the 4th quarter. TD Asset Management Inc now owns 324,546 shares of the company’s stock worth $138,860,000 after purchasing an additional 22,715 shares in the last quarter. Finally, Epoch Investment Partners Inc. raised its position in Chemed by 4.9% in the fourth quarter. Epoch Investment Partners Inc. now owns 322,408 shares of the company’s stock valued at $137,945,000 after purchasing an additional 15,133 shares during the last quarter. Institutional investors own 95.85% of the company’s stock.

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.